ACCESS PACK EXPO XPRESS ONLINE TODAY. Content is available on-demand through November 30th.

Major Medical Centers Are Nixing Aduhelm

The controversial new Alzheimer’s drug may be FDA-approved, but there’s no shortage of critics.

Last month, we discussed Aduhelm, Biogen’s recently-approved Alzheimer’s drug that received pushback from medical professionals who believe the FDA put the cart ahead of the horse. Now, according to a New York Times article, two major medical centers, Cleveland Clinic and Mount Sinai, have decided not to administer the drug to patients. 

Cleveland Clinic, one of the most well-respected medical centers in America, released a statement saying that a panel of its experts reviewed scientific evidence on the drug’s safety and efficacy and decided not to carry it at this time. However, a spokesperson for the clinic noted that individual physicians can prescribe Aduhelm, but patients would have to receive the monthly intravenous infusion elsewhere. 

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub